MedicalResearch.com Interview with:
Maria Domenica Cappellini, M.D.
Principal Investigator, BELIEVE Clinical Trial
Fondazione IRCCS Ca’ Granda Policlinico Hospital
University of Milan, Milan, Italy
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Beta thalassemia is a severe, inherited hemoglobinophathy due to a reduced production of hemoglobin. Standard of care is blood transfusion and iron chelation to remove the accumulated iron by transfusion. This is a very demanding treatment.
Therefore, there is the need to find new approaches for treating these patients. The BELIEVE study showed that the experimental drug luspatercept significantly reduced the need for blood transfusions in patients with beta thalassemia. More than 70 percent of patients who received luspatercept were able to cut blood transfusions by at least one-third over any consecutive 12-week period
MedicalResearch.com: What should readers take away from your report?
Response: The efficacy of luspatercept in reducing the transfusion burden in beta thalassemia patients.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: We are just at the beginning. We need to monitor the patients’ treatment in order to confirm the efficacy of the drug, to prove the duration of response and to identify the different patterns of response in order to identify those patients who could benefit more from this treatment.
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.